Oncolytic virotherapy

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,771 · see citing works

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

Fang, J. Q., Nakamura, H., & Maeda, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,573 · see citing works

Delivering nanomedicine to solid tumors

Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,196 · see citing works

A diverse range of gene products are effectors of the type I interferon antiviral response

Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P. D., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,439 · see citing works

Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment

Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438 · see citing works

Polymer conjugates as anticancer nanomedicines

Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956 · see citing works

Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness

Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689 · see citing works

Phagocytosis of Microbes: Complexity in Action

Underhill, D. M., & Ozinsky, A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.103001.114744 · Cited by 1,124 · see citing works

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

Martuza, R. L., Malick, A., Markert, J. M., et al. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,058 · see citing works

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023 · see citing works

A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules

Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902 · see citing works

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl, D., Lichty, B., TENOEVER, B., Paterson, J., Power, A., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 894 · see citing works

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

Stojdl, D. F., Lichty, B. D., Knowles, S., Marius, R. M., Atkins, H. L., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 818 · see citing works

History of Oncolytic Viruses: Genesis to Genetic Engineering

Kelly, E. J., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763 · see citing works

Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture

Fox, M. E., Szoka, F. C., & Fréchet, J. M. J. (2009) · Accounts of Chemical Research · doi:10.1021/ar900035f · Cited by 745 · see citing works

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · see citing works

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

Bessis, N., Garcia-Cozar, F. J., & Boissier, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 636 · see citing works

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Senzer, N. N., Kaufman, H. L., AMATRUDA, T. T., Nemunaitis, M., Reid, T. R., Daniels, G. A., Gonzalez, R. C., Glaspy, J. A., Whitman, E. D., Harrington, K. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 617 · see citing works

Tumour vascular targeting

Neri, D., & Bicknell, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1627 · Cited by 599 · see citing works

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584 · see citing works

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Breitbach, C. J., Burke, J., Jonker, D. J., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J. J., Hwang, T.-H., Moon, A., Patt, R. H., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 552 · see citing works

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

Park, B.-H., Hwang, T.-H., Liu, T., Sze, D. Y., Kim, J., Kwon, H., Oh, S. Y., Han, S., Yoon, J.-H., Hong, S. H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 522 · see citing works

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

Liu, T., Galanis, E., & Kirn, D. H. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450 · see citing works

Blood clearance rates of adenovirus type 5 in mice

Alemany, R., Suzuki, K., & Curiel, D. T. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2605 · Cited by 414 · see citing works

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402 · see citing works

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

Cattaneo, R., Miest, T. S., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373 · see citing works

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

Mastrangelo, M. J., Maguire, H., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353 · see citing works

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

Jacobs, A. K., Voges, J., Reszka, R. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05904-9 · Cited by 351 · see citing works

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

Ikeda, K., Ichikawa, T., Wakimoto, H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 340 · see citing works

Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver

Tao, N., Gao, G., Parr, M. J., Johnston, J., Baradet, T. C., Wilson, J. M., Barsoum, J., & Fawell, S. E. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0227 · Cited by 321 · see citing works

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

Dingli, D., Peng, K.-W., Harvey, M. E., et al. (2003) · Blood · doi:10.1182/blood-2003-07-2233 · Cited by 320 · see citing works

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

Galanis, E., Hartmann, L. C., Cliby, W. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2762 · Cited by 318 · see citing works

Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus

Díaz, R. M., Galivo, F., Kottke, T. J., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G. N., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 263 · see citing works

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0196 · Cited by 259 · see citing works

Rescue and propagation of fully retargeted oncolytic measles viruses

Nakamura, T., Peng, K.-W., Harvey, M. E., Greiner, S. M., Lorimer, I. A. J., James, C. D., & Russell, S. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1060 · Cited by 253 · see citing works

Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy

Thorne, S. H., Negrin, R. S., & Contag, C. H. (2006) · Science · doi:10.1126/science.1121411 · Cited by 252 · see citing works

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

Melcher, A. A., Parato, K. A., Rooney, C. M., & Bell, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.65 · Cited by 232 · see citing works

Engineering microRNA responsiveness to decrease virus pathogenicity

Kelly, E. J., Hadac, E. M., Greiner, S. M., et al. (2008) · Nature Medicine · doi:10.1038/nm.1776 · Cited by 217 · see citing works

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity

Chang, H.-M., Paulson, M. S., Holko, M., Rice, C. M., Williams, B. R. G., Marié, I., & Levy, D. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400567101 · Cited by 212 · see citing works

Relaxin Expression From Tumor-Targeting Adenoviruses and Its Intratumoral Spread, Apoptosis Induction, and Efficacy

Kim, J.-H., Lee, Y.-S., Kim, H., Huang, J.-H., Yoon, A. R., & Yun, C. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj397 · Cited by 211 · see citing works

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

Guedan, S., Rojas, J. J., Gros, A., Mercadé, E., Cascalló, M., & Alemany, R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.79 · Cited by 206 · see citing works

Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein

Doronin, K., Tóth, K., Kuppuswamy, M. N., Ward, P. A., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206 · see citing works

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Mader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1292 · Cited by 205 · see citing works

Targeting Tumor Vasculature With an Oncolytic Virus

Breitbach, C. J., Silva, N. S. D., Falls, T. J., Aladl, U. E., Evgin, L., Paterson, J. M., Sun, Y., Roy, D. G., Rintoul, J. L., Daneshmand, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.26 · Cited by 204 · see citing works

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

Green, N. K., Herbert, C. W., Hale, S. J. M., Hale, A., Mautner, V., Harkins, R. N., Hermiston, T. W., Ulbrich, K., Fisher, K., & Seymour, L. W. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302295 · Cited by 204 · see citing works

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

Thorne, S. H., Hwang, T.-H., O’Gorman, W. E., Bartlett, D. L., Sei, S., Kanji, F., Brown, C. W., Werier, J. A., Cho, J.-H., Lee, D.-E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32727 · Cited by 204 · see citing works

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

Kuhn, I., Harden, P., Bauzon, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002409 · Cited by 200 · see citing works

Viruses as anticancer drugs

Russell, S. J., & Peng, K.-W. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.005 · Cited by 186 · see citing works

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis

Nguyên, T. L.-A., Abdelbary, H., Arguello, M., Breitbach, C. J., Léveillé, S., Diallo, J., Yasmeen, A., Bismar, T. A., Kirn, D. H., Falls, T. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803988105 · Cited by 183 · see citing works

Interferon, Mx, and viral countermeasures

Haller, O., Kochs, G., & Weber, F. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.001 · Cited by 179 · see citing works

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

Qiao, J., Wang, H., Kottke, T. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1510 · Cited by 175 · see citing works

Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy

Kurozumi, K., Hardcastle, J. J., Thakur, R., Yang, M., Christoforidis, G. A., Fulci, G., Hochberg, F. H., Weissleder, R., Carson, W. E., Chiocca, E. A., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm229 · Cited by 172 · see citing works

Measles Virus for Cancer Therapy

Russell, S. J., & Peng, K.-W. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70617-5_11 · Cited by 172 · see citing works

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

Peng, K.-W., Facteau, S., Wegman, T. R., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-527 · Cited by 162 · see citing works

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

Otsuki, A., Patel, A. K., Kasai, K., Suzuki, M., Kurozumi, K., Chiocca, E. A., & Saeki, Y. (2008) · Molecular Therapy · doi:10.1038/mt.2008.155 · Cited by 157 · see citing works

Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant

Ikeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4765-4775.2000 · Cited by 154 · see citing works

Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

Rudin, C. M., Poirier, J. T., Senzer, N. N., Stephenson, J., Loesch, D. M., Burroughs, K. D., Reddy, P. S., Hann, C. L., & Hallenbeck, P. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1706 · Cited by 153 · see citing works

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

Heo, J., Breitbach, C. J., Moon, A., Kim, C. W., Patt, R., Kim, M. K., Lee, Y. K., Oh, S. Y., Woo, H. Y., Parato, K. A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.39 · Cited by 151 · see citing works

Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis

Dorer, D. E., & Nettelbeck, D. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.013 · Cited by 150 · see citing works

PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum

Croyle, M. A., Callahan, S. M., Auricchio, A., Schumer, G., Linse, K. D., Wilson, J. M., Brunner, L. J., & Kobinger, G. P. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.912-921.2004 · Cited by 148 · see citing works

Chemical control of protein stability and function in living mice

Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J., & Thorne, S. H. (2008) · Nature Medicine · doi:10.1038/nm.1754 · Cited by 147 · see citing works

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study

Garcı́a-Castro, J., Alemany, R., Cascalló, M., et al. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.4 · Cited by 141 · see citing works

Phase I Study of Noninvasive Imaging of Adenovirus-mediated Gene Expression in the Human Prostate

Barton, K. N., Stricker, H. J., Brown, S. L., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.172 · Cited by 140 · see citing works

Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma

Wong, R. J., Patel, S. G., Kim, S., et al. (2001) · Human Gene Therapy · doi:10.1089/10430340150218396 · Cited by 135 · see citing works

A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication

Edge, R. E., Falls, T. J., Brown, C. W., Lichty, B. D., Atkins, H. L., & Bell, J. C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.130 · Cited by 135 · see citing works

Rapid Kupffer cell death after intravenous injection of adenovirus vectors

Manickan, E., Smith, J. S., Tian, J., Eggerman, T. L., Lozier, J. N., Müller, J., & Byrnes, A. P. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.007 · Cited by 134 · see citing works

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production

Alain, T., Lun, X. Q., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F. J., Lemay, C. G., Roy, D. G., Bell, J. C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912344107 · Cited by 133 · see citing works

Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells

Cawood, R., Chen, H. H., Carroll, F., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000440 · Cited by 133 · see citing works

Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing

Boeuf, F. L., Diallo, J., McCart, J. A., Thorne, S. H., Falls, T. J., Stanford, M. M., Kanji, F., Auer, R. C., Brown, C. W., Lichty, B. D., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.44 · Cited by 130 · see citing works

Biology of the human malignant lymphomas I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas

Epstein, A. L., & Kaplan, H. S. (1974) · Cancer · doi:10.1002/1097-0142(197412)34:6 · Cited by 129 · see citing works

Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors

Muthana, M., Giannoudis, A., Scott, S. D., Fang, H., Coffelt, S. B., Morrow, F. J., Murdoch, C., Burton, J., Cross, N. A., Burke, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2349 · Cited by 127 · see citing works

Large-Plaque Mutants of Sindbis Virus Show Reduced Binding to Heparan Sulfate, Heightened Viremia, and Slower Clearance from the Circulation

Byrnes, A. P., & Griffin, D. E. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.644-651.2000 · Cited by 126 · see citing works

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

Ong, H. T., Hasegawa, K., Dietz, A. B., Russell, S. J., & Peng, K.-W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302880 · Cited by 125 · see citing works

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

Ilett, E. J., Prestwich, R. J. D., Kottke, T. J., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.29 · Cited by 123 · see citing works

Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model

Ling, X., Marini, F. C., Konopleva, M. Y., Schober, W. D., Shi, Y., Burks, J. K., Clise-Dwyer, K., Wang, R., Zhang, W., Yuan, X., et al. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0041-8 · Cited by 122 · see citing works

Intratumoral Spread of Wild-Type Adenovirus Is Limited After Local Injection of Human Xenograft Tumors: Virus Persists and Spreads Systemically at Late Time Points

Sauthoff, H., Hu, J. S., Maca, C., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403321467199 · Cited by 122 · see citing works

Human reporter genes: potential use in clinical studies

Serganova, I. S., Ponomarev, V., & Blasberg, R. G. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.05.009 · Cited by 118 · see citing works

DIVISION OF MICROBIOLOGY: PRESENT STATUS OF ONCOLYTIC VIRUS STUDIES*

Southam, C. M. (1960) · Transactions of the New York Academy of Sciences · doi:10.1111/j.2164-0947.1960.tb00739.x · Cited by 115 · see citing works

Advances in mesenchymal stem cell-mediated gene therapy for cancer

Dwyer, R. M., Khan, S., Barry, F., O’Brien, T., & Kerin, M. J. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt25 · Cited by 115 · see citing works

Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus

Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., & Barry, M. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.028 · Cited by 112 · see citing works

Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting

Kelly, E. J., Nace, R. A., Barber, G. N., & Russell, S. J. (2009) · Journal of Virology · doi:10.1128/jvi.01788-09 · Cited by 111 · see citing works

Clinical development directions in oncolytic viral therapy

Eager, R. M., & Nemunaitis, J. J. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.7 · Cited by 110 · see citing works

Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin

Lun, X. Q., Zhou, H., Alain, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1214 · Cited by 110 · see citing works

Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways

Naik, S., & Russell, S. J. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903170653 · Cited by 108 · see citing works

Molecular targets for existing and novel immunosuppressive drugs

Stepkowski, S. M. (2000) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399400001769 · Cited by 108 · see citing works

Transcriptional targeting of herpes simplex virus for cell-specific replication

Miyatake, S., Iyer, A., Martuza, R. L., et al. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5124-5132.1997 · Cited by 108 · see citing works

Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.

Kumar, C. C., Huiming-Nie, C. P. R., Rogers, C. P., Malkowski, M., Maxwell, E., Catino, J. J., & Armstrong, L. (1997) · PubMed · Cited by 106 · see citing works

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma

Pulido, J. S., Kottke, T. J., Thompson, J., Galivo, F., Wongthida, P., Díaz, R. M., Rommelfanger, D. M., Ilett, E. J., Pease, L. R., Pandha, H., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2157 · Cited by 105 · see citing works

Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin

Lun, X., Alain, T., Zemp, F. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1510 · Cited by 105 · see citing works

MicroRNA-sensitive Oncolytic Measles Viruses for Cancer-specific Vector Tropism

Leber, M. F., Bossow, S., Léonard, V. H. J., Zaoui, K., Grossardt, C., Frenzke, M. E., Miest, T. S., Sawall, S., Cattaneo, R., Kalle, C. V., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.55 · Cited by 102 · see citing works

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers

Diallo, J., Bœuf, F. L., Lai, F. W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.67 · Cited by 101 · see citing works

Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus

Shashkova, E. V., Doronin, K., Senac, J. S., & Barry, M. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0488 · Cited by 99 · see citing works

Variola and Monkeypox Viruses Utilize Conserved Mechanisms of Virion Motility and Release That Depend on Abl and Src Family Tyrosine Kinases

Reeves, P. M., Smith, S. K., Olson, V. A., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01814-10 · Cited by 98 · see citing works

Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization

Ilett, E. J., Bárcena, M., Errington‐Mais, F., Griffin, S. D. C., Harrington, K. J., Pandha, H., Coffey, M. C., Selby, P. J., Limpens, R. W. A. L., Mommaas, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3266 · Cited by 97 · see citing works

Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism

Muik, A., Kneiske, I., Werbizki, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02511-10 · Cited by 96 · see citing works

Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses

Peng, K.-W., Myers, R. M., Greenslade, A., et al. (2012) · Gene Therapy · doi:10.1038/gt.2012.31 · Cited by 96 · see citing works

Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors

Kottke, T. J., Errington‐Mais, F., Pulido, J. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2390 · Cited by 95 · see citing works

Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models

Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Roey, M. V., & Jooss, K. U. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4732 · Cited by 95 · see citing works

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

Harrington, K. J., Vile, R. G., Melcher, A. A., Chester, J. D., & Pandha, H. S. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.02.006 · Cited by 93 · see citing works

MicroRNAs and the Regulation of Vector Tropism

Kelly, E. J., & Russell, S. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.288 · Cited by 93 · see citing works

The Complement Response Against an Oncolytic Virus Is Species-Specific in Its Activation Pathways

Wakimoto, H., Ikeda, K., Abé, T., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0547 · Cited by 93 · see citing works

Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion

Kirn, D. H., Wang, Y., Liang, W., Contag, C. H., & Thorne, S. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6515 · Cited by 89 · see citing works

In vivo imaging and tumor therapy with the sodium iodide symporter

Dingli, D., Russell, S. J., & Morris, J. C. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10714 · Cited by 88 · see citing works

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

Qiao, J., Wang, H., Kottke, T. J., Díaz, R. M., Willmon, C. L., Hudacek, A. W., Thompson, J., Parato, K., Bell, J. C., Naik, J., et al. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303098 · Cited by 87 · see citing works

Curative one-shot systemic virotherapy in murine myeloma

Naik, S., Nace, R. A., Federspiel, M., Barber, G., Peng, K., & Russell, S. (2012) · Leukemia · doi:10.1038/leu.2012.70 · Cited by 87 · see citing works

Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor

Morrison, J., Briggs, S. S., Green, N. H., Fisher, K. D., Šubr, V., Ulbrich, K., Kehoe, S. T., & Seymour, L. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300363 · Cited by 86 · see citing works

Scavenger Receptor A: A New Route for Adenovirus 5

Haisma, H. J., Boesjes, M., Beerens, A. M., van der Strate, B. W. A., Curiel, D. T., Plüddemann, A., Gordon, S., & Bellu, A. R. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8000974 · Cited by 84 · see citing works

Engineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune Response

Haralambieva, I. H., Iankov, I. D., Hasegawa, K., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300076 · Cited by 83 · see citing works

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice

Kottke, T. J., Hall, G. D., Pulido, J. S., Díaz, R. M., Thompson, J., Chong, H., Selby, P. J., Coffey, M. C., Pandha, H., Chester, J. D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41431 · Cited by 83 · see citing works

Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21

Au, G. G., Lindberg, A., Barry, R. D., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.6.1471 · Cited by 83 · see citing works

Exponential Enhancement of Oncolytic Vesicular Stomatitis Virus Potency by Vector-mediated Suppression of Inflammatory Responses In Vivo

Altomonte, J., Wu, L., Chen, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300343 · Cited by 80 · see citing works

Development of PEGylated adenovirus vector with targeting ligand

Eto, Y., Yoshioka, Y., Mukai, Y., Okada, N., & Nakagawa, S. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.08.025 · Cited by 78 · see citing works

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

MacTavish, H., Diallo, J., Huang, B., Stanford, M. M., Bœuf, F. L., Silva, N. D., Cox, J. A., Simmons, J.-G., Guimond, T., Falls, T. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014462 · Cited by 76 · see citing works

Replication-competent retrovirus vectors for cancer gene therapy

Tai, C.-K. (2007) · Frontiers in bioscience · doi:10.2741/2910 · Cited by 76 · see citing works

HPMA copolymers for masking and retargeting of therapeutic viruses☆

Fisher, K. D., & Seymour, L. W. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.12.003 · Cited by 74 · see citing works

Biochemical Characterization of the Binding of Echistatin to Integrin αvβ3 Receptor

Kumar, C. C., Nie, H., Rogers, C. P., Malkowski, M., Maxwell, E., Catino, J. J., & Armstrong, L. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37071-5 · Cited by 73 · see citing works

Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2

Kottke, T. J., Thompson, J., Díaz, R. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1688 · Cited by 72 · see citing works

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

Power, A., & Bell, J. C. (2008) · Gene Therapy · doi:10.1038/gt.2008.40 · Cited by 71 · see citing works

Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers

Liu, C., Russell, S. J., & Peng, K.-W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.43 · Cited by 70 · see citing works

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G. F. L., Boyle, R. W., & Neri, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.78 · Cited by 70 · see citing works

Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor

Jing, Y., Tong, C., Zhang, J., Nakamura, T., Iankov, I. D., Russell, S. J., & Merchan, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2628 · Cited by 68 · see citing works

The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis

Brown, C. W., Stephenson, K. B., Hanson, S. J., Kucharczyk, M. J., Duncan, R., Bell, J. C., & Lichty, B. D. (2008) · Journal of Virology · doi:10.1128/jvi.01921-08 · Cited by 59 · see citing works

Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor

Tseng, J.-C., Granot, T., DiGiacomo, V., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.70 · Cited by 58 · see citing works

Oncolytic Herpes Simplex Virus Vectors and Chemotherapy: Are Combinatorial Strategies More Effective for Cancer?

Kanai, R., Wakimoto, H., Cheema, T. A., & Rabkin, S. D. (2010) · Future Oncology · doi:10.2217/fon.10.18 · Cited by 58 · see citing works

Oncolytic (replication-competent) adenoviruses as anticancer agents

Tóth, K., Dhar, D., & Wold, W. S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903559822 · Cited by 57 · see citing works

Conditional and reversible disruption of essential herpesvirus proteins

Glaß, M., Busche, A., Wagner, K., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1346 · Cited by 55 · see citing works

The host response to cancer virotherapy.

Ea, C. (2008) · PubMed · Cited by 55 · see citing works

Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus

Kottke, T. J., Galivo, F., Wongthida, P., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.83 · Cited by 54 · see citing works

Replicating vectors for cancer therapy: a question of strategy.

Russell, S. J. (1994) · PubMed · Cited by 53 · see citing works

Retargeting Vesicular Stomatitis Virus Using Measles Virus Envelope Glycoproteins

Ayala-Bretón, C., Barber, G. N., Russell, S. J., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.146 · Cited by 52 · see citing works

Innate immune response and viral interference strategies developed by Human Herpesviruses

Vandevenne, P., Sadzot‐Delvaux, C., & Piette, J. G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.001 · Cited by 52 · see citing works

Infection and Killing of Multiple Myeloma by Adenoviruses

Senac, J. S., Doronin, K., Russell, S. J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.082 · Cited by 51 · see citing works

Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors

Lee, C., Bu, L., Benedetti, A. D., Williams, B. J., Rennie, P. S., & Jia, W. W.-G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.26 · Cited by 50 · see citing works

Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices

Sanz, L., Kristensen, P. K., Blanco, B., Facteau, S., Russell, S. J., Winter, G. P., & Álvarez‐Vallina, L. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301725 · Cited by 50 · see citing works

A Single Mutation in the E2 Glycoprotein Important for Neurovirulence Influences Binding of Sindbis Virus to Neuroblastoma Cells

Lee, P., Knight, R. L., Smit, J. M., Wilschut, J., & Griffin, D. E. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6302-631-.2002 · Cited by 48 · see citing works

Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer

Kottke, T. J., Díaz, R. M., Kaluza, K. M., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.212 · Cited by 47 · see citing works

Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.

Yun, C. (2008) · PubMed · Cited by 46 · see citing works

Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry Disease

Ziegler, R. J., Li, C. Q., Cherry, M., Zhu, Y., Hempel, D. M., van Rooijen, N., Ioannou, Y. A., Desnick, R. J., Goldberg, M. A., Yew, N. S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340252939041 · Cited by 45 · see citing works

Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer

Morrison, J., Briggs, S. S., Green, N. K., Thoma, C., Fisher, K. D., Kehoe, S. T., & Seymour, L. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.167 · Cited by 40 · see citing works

Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control

Stoff‐Khalili, M. A., Rivera, Á. A., Nedeljkovic-Kurepa, A., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9587-7 · Cited by 39 · see citing works

Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus

Shashkova, E. V., May, S. M., Doronin, K., & Barry, M. A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.217 · Cited by 38 · see citing works

Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences

Sugio, K., Sakurai, F., Katayama, K., Tashiro, K., Matsui, H., Kawabata, K., Kawase, A., Iwaki, M., Hayakawa, T., Fujiwara, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2008 · Cited by 38 · see citing works

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy

Chen, N. G., Bellone, C. J., Schriewer, J. M., Owens, G., Fredrickson, T. N., Parker, S., & Buller, R. M. L. (2010) · Virology · doi:10.1016/j.virol.2010.10.021 · Cited by 38 · see citing works

MicroRNA Controlled Adenovirus Mediates Anti-Cancer Efficacy without Affecting Endogenous MicroRNA Activity

Cawood, R., Wong, S. L., Di, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016152 · Cited by 37 · see citing works

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells

Koski, A., Rajecki, M., Guse, K., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1373 · Cited by 37 · see citing works

Interferon-stimulated gene ISG12b2 is localized to the inner mitochondrial membrane and mediates virus-induced cell death

Lu, M., & Liao, F. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.160 · Cited by 36 · see citing works

Intravascularly Administered RGD-Displaying Measles Viruses Bind to and Infect Neovessel Endothelial Cells In Vivo

Ong, H. T., Trejo, T. R., Pham, L., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.39 · Cited by 36 · see citing works

A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy

Schoofs, G. M., Monica, T. J., Ayala, J., et al. (1998) · Cytotechnology · doi:10.1023/a:1008021428969 · Cited by 34 · see citing works

Combining oncolytic virotherapy and tumour vaccination

Bridle, B. W., Hanson, S. J., & Lichty, B. D. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.02.009 · Cited by 34 · see citing works

Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication

Passer, B. J., Cheema, T. A., Zhou, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0155 · Cited by 34 · see citing works

Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation

Olière, S., Arguello, M., Mésplède, T., Tumilasci, V. F., Nakhaei, P., Stojdl, D. F., Sonenberg, N., Bell, J. C., & Hiscott, J. B. (2008) · Journal of Virology · doi:10.1128/jvi.02601-07 · Cited by 32 · see citing works

Cardiac gene therapy in large animals: bridge from bench to bedside

Ishikawa, K., Tilemann, L. M., Ladage, D., Agüero, J., Leonardson, L., Fish, K. M., & Kawase, Y. (2012) · Gene Therapy · doi:10.1038/gt.2012.3 · Cited by 31 · see citing works

Bioreactor Production of Recombinant Herpes Simplex Virus Vectors

Knop, D. R., & Harrell, H. (2007) · Biotechnology Progress · doi:10.1021/bp060373p · Cited by 31 · see citing works

Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7

Barnett, F. H., Rainov, N. G., Ikeda, K., et al. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700003 · Cited by 31 · see citing works

Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma

Mastrangelo, M. J., Maguire, H. C., Jr., & Lattime, E. C. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_34 · Cited by 31 · see citing works

Novel tumour‐specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors

Foka, P., Pourchet, A., Hernández-Alcoceba, R., et al. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1519 · Cited by 29 · see citing works

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins

Bachtarzi, H., Stevenson, M., Šubr, V., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.011 · Cited by 29 · see citing works

Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay

Yang, X., Chen, E., Jiang, H., Muszynski, K. W., Harris, R. D., Giardina, S. L., Gromeier, M., Mitra, G., & Soman, G. (2008) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.09.020 · Cited by 29 · see citing works

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus

Roos, F. C., Roberts, A. M., Hwang, I. I. L., Moriyama, E. H., Evans, A. J., Sybingco, S. S., Watson, I. R., Carneiro, L. A. M., Gedye, C. A., Girardin, S. E., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000081 · Cited by 29 · see citing works

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

Israyelyan, A., Chouljenko, V. N., Baghian, A., David, A. T., Kearney, M. T., & Kousoulas, K. G. (2008) · Virology Journal · doi:10.1186/1743-422x-5-68 · Cited by 28 · see citing works

Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines.

Lewis, J. A., Brown, E. L., & Duncan, P. A. (2006) · PubMed · Cited by 27 · see citing works

Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights

Patel, B., Dey, A., Ghorani, E., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.44 · Cited by 27 · see citing works

Pharmacological Interventions for Improving Adenovirus Usage in Gene Therapy

Haisma, H. J., & Bellu, A. R. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100310h · Cited by 26 · see citing works

Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy

Hoffmann, D., & Wildner, O. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0128 · Cited by 22 · see citing works

Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelial–epithelial Syncytia

Chen, H. H., Cawood, R., El-Sherbini, Y., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.209 · Cited by 18 · see citing works

Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines

Zhang, M. (2011) · Oncology Reports · doi:10.3892/or.2011.1306 · Cited by 13 · see citing works

Ligand-directed Cancer Gene Therapy to Angiogenic Vasculature

Driessen, W. H. P., Ozawa, M. G., Arap, W., et al. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67004-8 · Cited by 6 · see citing works

The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · see citing works

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869 · see citing works

The Basis of Oncoimmunology

Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843 · see citing works

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · see citing works

Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · see citing works

Tunable and reversible drug control of protein production via a self-excising degron

Chung, H. K., Jacobs, C. L., Huo, Y., Yang, J., Krumm, S. A., Plemper, R. K., Tsien, R. Y., & Lin, M. Z. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1869 · Cited by 233 · see citing works

CRISPR-Cas9: a new and promising player in gene therapy

Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200 · see citing works

Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors

Merienne, N., Douce, J. L., Faivre, E., Déglon, N., & Bonvento, G. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00106 · Cited by 58 · see citing works

Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses

Miller, A., Nace, R., Ayala-Breton C, C., Steele, M., Bailey, K., Peng, K. W., & Russell, S. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.219 · Cited by 38 · see citing works

HDACi delivery reprograms tumor-infiltrating myeloid cells to eliminate antigen-loss variants

Nguyen, A., Ho, L., Workenhe, S. T., Chen, L., Samson, J., Walsh, S. R., Pol, J., Bramson, J. L., & Wan, Y. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.040 · Cited by 29 · see citing works

Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer

Rao, M. F. S., Ahmed, B., & Qadir, M. I. (2023) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023048962

Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses

Goradel, N. H., Alizadeh, A., Hosseinzadeh, S., Taghipour, M., Ghesmati, Z., Arashkia, A., & Negahdari, B. (2021) · Future Oncology · doi:10.2217/fon-2021-0802 · Cited by 33 · see citing works

Treatment of Metastatic Neuroblastoma with Mesenchymal Stem Cell‐Based Oncolytic Virotherapy

Ramírez, M. R., & Garcı́a-Castro, J. (2013) · doi:10.1002/9781118660423.ch8

Enhancing oncolytic virotherapy: Observations from a Voronoi Cell-Based model

Jenner, A. L., Frascoli, F., Coster, A. C. F., & Kim, P. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110052 · Cited by 25 · see citing works

Mesenchymal stem cells as carrier cells to enable effective intratumoral delivery of oncolytic virus for oncolytic virotherapy: a systematic review

Jittprasong, C. (2022) · arXiv (Cornell University) · doi:10.48550/arxiv.2204.01238